Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12 Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-products (Budesonide and Formoterol) in Adolescents (at Least 12 Years of Age) and Adults With Asthma - SPRUCE 160/4.5

Next Previous
Trial Profile

A 12 Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-products (Budesonide and Formoterol) in Adolescents (at Least 12 Years of Age) and Adults With Asthma - SPRUCE 160/4.5

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Budesonide; Formoterol
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms SPRUCE
  • Sponsors AstraZeneca

    • Most Recent Events

    • 07 Mar 2016 Post hoc analysis results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 04 Mar 2014 Results of a pooled analysis of this trial and another trial (see profile 700035455) presented at the 70th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 26 Feb 2013 Results comparing patients with versus without fixed airflow obstruction presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top